BIOMAT Database Logo BIOMAT Database Logo

[New analogs of deoxyadenosine for treatment of lymphoid malignancies]. 1992

T Robak
II Klinika Chorób Wewnetrznych AM, Lodzi.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D003839 Deoxyadenosines Adenosine molecules which can be substituted in any position, but are lacking one hydroxyl group in the ribose part of the molecule. Adenine Deoxyribonucleosides,Adenylyldeoxyribonucleosides,Deoxyadenosine Derivatives,Deoxyribonucleosides, Adenine,Derivatives, Deoxyadenosine
D005573 Formycins Pyrazolopyrimidine ribonucleosides isolated from Nocardia interforma. They are antineoplastic antibiotics with cytostatic properties.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D014740 Vidarabine A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus. Adenine Arabinoside,Ara-A,Arabinofuranosyladenine,Arabinosyladenine,9-beta-Arabinofuranosyladenine,9-beta-D-Arabinofuranosyladenine,Ara A,Vira-A,alpha-Ara A,alpha-D-Arabinofuranosyladenine,beta-Ara A,9 beta Arabinofuranosyladenine,9 beta D Arabinofuranosyladenine,Arabinoside, Adenine,Vira A,ViraA,alpha Ara A,alpha D Arabinofuranosyladenine,beta Ara A
D017338 Cladribine An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. 2-Chloro-2'-deoxyadenosine,2-Chlorodeoxyadenosine,2'-Deoxy-2-chloroadenosine,Leustatin

Related Publications

T Robak
Pentostatin and purine analogs for indolent lymphoid malignancies.
April 2006, Future oncology (London, England),
T Robak
New chemotherapeutics strategies for the treatment of indolent lymphoid malignancies.
October 1999, Seminars in hematology,
T Robak
Milatuzumab: a promising new agent for the treatment of lymphoid malignancies.
January 2009, Expert opinion on investigational drugs,
T Robak
Duvelisib, a new PI3K inhibitor for lymphoid malignancies.
October 2020, Clinical advances in hematology & oncology : H&O,
T Robak
Local treatment for lymphoid malignancies of the eye.
December 2009, Anti-cancer agents in medicinal chemistry,
T Robak
Targeting BCL2 for the treatment of lymphoid malignancies.
July 2014, Seminars in hematology,
T Robak
[Lymphoid malignancies: progress in diagnosis and treatment. Topics: III. Diagnosis and treatment; 5. Developmental status and perspective of new drugs for lymphoid malignancies in Japan].
July 2011, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
T Robak
2-Chlorodeoxyadenosine treatment of lymphoid malignancies.
February 1992, Blood,
T Robak
New developments in non-Hodgkin lymphoid malignancies.
April 2021, Pathology,
T Robak
[Lymphoid malignancies: progress in diagnosis and treatment. Topics: II. Basic knowledge of lymphoid malignancies; 1. Classification of lymphoid malignancy].
July 2011, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Copied contents to your clipboard!